Sarepta Therapeutics (SRPT) Defended at Cantor Fitzgerald
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Price: $19.22 --0%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young is reiterating their conviction on Sarepta Therapeutics (NASDAQ: SRPT) amid today's weakness.
The firm reiterated an Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Cantor Fitzgerald, Alethia YoungSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
